Page 2 1 Todos los derechos reservados Rev. Chil. Psiquiatr ...

Treatment of Schizophrenia, Part 1:Update 2012 on the acute treatment ofschizophrenia and the management oftreatment resistance. The World Journalof Biological Psychiatry, 2012; 13:318–378.5. Falkai P, Wobrock T, Lieberman J,Glenthoj B, Gattaz WF, Moller HJ.2006. World Federation of Societies ofBiological Psychiatry (WFSBP) guidelinesfor biological treatment of schizophrenia,part 2: long-term treatmentof schizophrenia.World J Biol Psychiatry7:5–406. Kane J, Honigfeld G, Singer J, MeltzerH. 1988a. Clozapine for the treatmentresistantschizophrenic. A doubleblindcomparison with chlorpromazine.Arch Gen Psychiatry 45: 789–796.7. NICE. 2002. National Institute of Excellence.Guidance on the use of newer(atypical) antipsychotic drugs for thetreatment of schizophrenia. TechnologyAppraisal Guideance No. 54. www.nice.org.ik.8. NICE. 2010. The NICE Guideline oncore interventions in the treatmentand management of schizophrenia inadults in primary and secondary care(updated edition). London: The BritishPsychological Society.9. Meltzer HY. 1990. Defining treatmentrefractoriness in schizophrenia. SchizophrBull 16:563–565.10. T. Suzuki et al. Defining treatment-resistantschizophrenia and response toantipsychotics: A review and recommendation/ Psychiatry Rcesearch 197(2012).11. T. Suzuki et al. Treatment resistantschizophrenia and response to antipsychotics:A review. SchizophreniaResearch 133 (2011).12. Findling RL, Frazier JA, Gerbino-RosenG, Kranzler HN, Kumra S, KratochvilCJ.Is There a Role for Clozapinein the Treatment of Children and Adolescents?J Am Acad Child AdolescPsychiatry. 2007 Mar;46(3):423-8.13. Kumra S, Kranzler H, Gerbino-RosenG, Kester HM, De Thomas C, KafantarisV, et al. 2008. Clozapine and“high-dose” olanzapine in refractoryearly-onset schizophrenia: a 12-weekrandomized and double-blind comparison.Biol Psychiatry 63:524–529.14. Marder S. 1995. Defining and characterisingtreatment-resistant schizophrenia.Eur Psychiatry 10(Suppl1):7–10s.15. McIlwain ME, Harrison J, Wheeler AJ,Russell BR. 2011. Pharmacotherapyfor treatment-resistant schizophrenia.Neuropsychiatr Dis Treat 7:135–149.16. Kennedy E, Kumar A, Datta SS. Antipsychoticmedication for childhood-onsetschizophrenia. Cochrane DatabaseSyst Rev. 2007 Jul 18;(3):CD004027.17. Eggers C, Bunk D. The long-termcourse of childhood-onset schizophrenia:a 42-year follow up. SchizophrBull 1997;23(1):105–17.18. Sikich L, Frazier JA, McClellan J, FindlingRL, Vitiello B, Ritz L, Ambler D,Puglia M, Maloney AE, Michael E, DeJong S, Slifka K, Noyes N, Hlastala S,Pierson L, McNamara NK, Delporto-Bedoya D, Anderson R, Hamer RM,Lieberman JA. Double-blind comparisonof first- and second-generationantipsychotics in early-onset schizophreniaand schizoaffective disorder:findings from the treatment of earlyonsetschizophrenia spectrum disorders(TEOSS) study. Am J Psychiatry.2008 Nov;165(11):1420-31. Epub 2008Sep 15.19. Englisch S, Zink M. 2012 TreatmentresistantSchizophrenia: EvidencebasedStrategies. Mens Sana MonogrJan;10(1):20-32.20. Lehman AF, Lieberman JA, Dixon LB,McGlashan TH, Miller AL, PerkinsDO, et al. 2004. Practice guideline forthe treatment of patients with schizophrenia,second edition. Am J Psychiatry161:1–56.21. Henry A. Nasrallah, MD. Randall F.White, MD, FRCPC. 2006. Esquizofreniaresistente al tratamiento. RET, Revistade Toxicomanías. No. 49 – 2006.22. American Academy of Child and AdolescentPsychiatry. Practice parameterfor the assessment and treatment ofTodos los derechos reservados Rev. Chil. Psiquiatr. Neurol. Infanc. Adolesc. / Volumen 24, Nº 1, Marzo 201369